Sign in

CIK 0001737287

  • Non-accelerated filer
  • Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
823562771
Phone
+1 650-457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Grant or award CHIEF FINANCIAL OFFICER acquired 790,000 shares (grant or award)
  2. 3 Insider Initial Statement of Ownership
  3. 4 Grant or award GENERAL COUNSEL acquired 435,834 shares (grant or award)
  4. 3 Insider Initial Statement of Ownership
  5. 4 Grant or award SVP, Finance acquired 11,401 shares (grant or award)
  6. 3 Insider Initial Statement of Ownership
  7. 4 Open-market sale Director sold 10,000 shares at $4.29 ($42,855)
  8. 4 Grant or award Director acquired 74,561 shares (grant or award)
  9. 4 Derivatives Options or other derivatives
  10. 4 Grant or award Director acquired 59,649 shares (grant or award)
  11. 4 Grant or award Director acquired 74,561 shares (grant or award)
  12. 4 Grant or award Director acquired 74,561 shares (grant or award)
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Grant or award Chief Technical Officer acquired 186,219 shares (grant or award)
  16. 3 Insider Initial Statement of Ownership
  17. 4 Grant or award VP, Corporate Counsel acquired 56,545 shares (grant or award)
  18. 3 Insider Initial Statement of Ownership
  19. 4 Grant or award Chief Technical Officer acquired 558,094 shares (grant or award)
  20. 4 Grant or award Chief Financial Officer acquired 558,094 shares (grant or award)

Page 5 of 14 · 275 filings